NMR-based Metabolic Profiling Identifies High Risk of MAFLD Patients With

Status Not yet recruiting

Clinical Trial Summary

This study aim to find out metabolic molecules in blood and urine which could identify high risk of advanced fibrosis in MAFLD patients via NMR-based metabolic profiling.

Clinical Trial Description

Metabolic dysfunction-associated fatty liver disease (MAFLD) is currently the most common liver disease in the world, with an incidence of 29.81% in China. Studies have shown that the severity of liver fibrosis is the most important predictor of disease progression in patients with MAFLD, and the more severe the degree of liver fibrosis, the worse the prognosis. Therefore, discovering non-invasive indicators that can predict the risk and identify people at high risk of MAFLD with advanced liver fibrosis is essential for early clinical intervention in order to improve their clinical prognosis. Some non-invasive tests like Vibration-controlled Transient Elastography (VCTE), Fibrosis-4 Index (FIB-4), and NAFLD fibrosis score (NFS) have been used to evaluate the liver fibrosis state in MAFLD patients, but lack of prospect in metabolic molecular level. Nuclear magnetic resonance(NMR)-based metabolomic profiling can identify and quantify significant biological molecules in tissue extracts, body fluids (blood, urine, cerebrospinal fluid, saliva, etc.), and secretions, and has wide applications in the study of cancer and other metabolic diseases. Therefore, this study intends to collect the demographic characteristics and serological indicators of MAFLD patients detected by liver VCTE, and use NMR profiling to perform metabolomic analysis on their peripheral blood and urine samples, in order to discover potential non-invasive biomarkers that can be used to predict and evaluate MAFLD advanced liver fibrosis, and further verify these MAFLD metabolomic indicators that may be associated with advanced liver fibrosis through multi-center clinical studies, in an attempt to provide ideal non-invasive biomarkers for MAFLD progression prediction and clinical intervention monitoring. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05734599
Study type	Observational
Source	Huazhong University of Science and Technology
Contact	Bin Cheng, Doctor
Phone	027-83663334
Email	bcheng@tjh.tjmu.edu.cn
Status	Not yet recruiting
Phase
Start date	March 1, 2023
Completion date	May 1, 2024

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT06188728` - Husk Fiber Intervention on Metabolic Health of Centrally Obese School Teachers	N/A
Recruiting	`NCT06007404` - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting	`NCT05081037` - Integrated Hyperglycaemia Incentivised Postnatal Surveillance Study (I-HIPS)	N/A
Recruiting	`NCT05318196` - Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
Not yet recruiting	`NCT05461144` - AI Models for Non-invasive Glycaemic Event Detection Using ECG in Type 1 Diabetics
Recruiting	`NCT05544266` - Rare and Atypical Diabetes Network
Recruiting	`NCT04039763` - RT-CGM in Young Adults at Risk of DKA	N/A
Active, not recruiting	`NCT05505994` - The Efficacy and Safety of DWP16001 in Combination With Metformin in T2DM Patients Inadequately Controlled on Metformin	Phase 3
Completed	`NCT03859934` - Metabolic Effects of Melatonin Treatment	Phase 1
Completed	`NCT03675360` - Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial	N/A
Recruiting	`NCT05711758` - Efficacy and Safety of Endoscopic Antral Myotomy as a Novel Weight Loss Procedure
Recruiting	`NCT05112029` - Metabolic Profile and Adipokine Levels in Young Hyperandrogenemic Females
Recruiting	`NCT03682640` - Azithromycin Insulin Diet Intervention Trial in Type 1 Diabetes	Phase 2
Completed	`NCT04854603` - Dairy Products With Reduced Sugar and Blood Glucose	N/A
Recruiting	`NCT06024291` - Reducing Circulating Sphingolipid Levels to Optimise Cardiometabolic Health - The SphingoFIT Trial	N/A
Recruiting	`NCT04904601` - Freeze-dried Kale to Reduce Metabolic Risk in Saudi Subjects	N/A
Recruiting	`NCT04109586` - Diet and Fat Mass After Traumatic Spinal Cord Injury	N/A
Recruiting	`NCT06009653` - Effect of Tirzepatide Plus Intensive Lifestyle Therapy on Body Weight and Metabolic Health in Latinos With Obesity	Phase 4
Completed	`NCT03067012` - Nutritional Safety and Metabolic Benefits of Oncometabolic Surgery for Obese Gastric Cancer Patients	N/A
Recruiting	`NCT03309423` - Is Venous to Arterial Conversion (v-TAC) of Blood Gas Reliable in Critical Ill Patients in the ICU?	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NMR-based Metabolic Profiling Identifies High Risk of MAFLD Patients With Advanced Fibrosis

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms